Panniculitis in patients treated with BRAF inhibitors: A case series

American Journal of Dermatopathology

Volumn 36, Issue 6, 2014, Pages 493-497

  Choy, Bonita ^a,b   Chou, Shaun ^c   Anforth, Rachael ^a,b   Fernández Peñas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Tissue Pathology and Diagnostic Oncology Pathology West Institute of Clinical Pathology and Medical Research ^*  (Australia)

Author keywords

BRAF inhibitor; dabrafenib; drug reaction; erythema nodosum; melanoma; panniculitis; vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; IBUPROFEN; MELOXICAM; POTASSIUM IODIDE; PREDNISONE; TRAMETINIB; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; FEMALE; FOLLICULITIS; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; KERATOSIS; LICHENOID; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PANNICULITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MELANOMA; PATHOLOGY; SKIN NEOPLASMS;

ADULT; AGED; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PANNICULITIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84902155756     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0000000000000023     Document Type: Article

References (20)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
2. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
3. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib ( GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153-1160.
4. Goldinger SM, Rinderknecht JD, Belloni B, et al. Cutaneous side effects ( cAE) of vemurafenib ( V): single-center cohort study of 28 metastatic melanoma ( mM) patients ( pts). J Clin Oncol. 2012;30( suppl 15):e19017.
5. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148:1183-1185.
6. Mattei PL, Alora-Palli MB, Kraft S, et al. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2013;24:530-537.
7. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30:2375-2383.
8. Zimmer L, Livingstone E, Hillen U, et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148:357-361.
9. Monfort JB, Pages C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res. 2012;22:399-401.
10. Kim GH, Levy A, Compoginis G. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol. 2013;40:667-669.
11. Dabner M, Harvey NT, Soma A, et al. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases. Pathology. 2012;44:661-664.
12. Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol. 2009;62:493-504.
13. Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colonystimulating factor ( G-CSF) therapy. Pediatr Dermatol. 2001;18:417-421.
14. de Masson A, Bouvresse S, Clerici T, et al. Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib. Ann Dermatol Venereol. 2011;138:135-139.
15. Cohen PR. Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. J Am Acad Dermatol. 2005;52:927-928.
16. Becherer K, Golda N, Feldman M, et al. Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms. J Cutan Pathol. 2009;36:1024-1026.
17. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366: 707-714.
18. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
19. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain ( BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:1087-1095.
20. Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive ( V600E/K) metastatic melanoma. Pigment Cell Melanoma Res. 2011;24:1020.